The Calcitonin Gene Related Peptide Type 1 Receptor pipeline drugs market research report outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Calcitonin Gene Related Peptide Type 1 Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

The report also covers products from therapy areas such as Central Nervous System, Dermatology, Undisclosed, and Cardiovascular which include the indications Migraine, Cluster Headache Syndrome (Cluster Headache), Diabetic Foot Ulcers, Rosacea, Unspecified, and Resistant Hypertension. It also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor targeted therapeutics development with respective active and dormant or discontinued products.

The Calcitonin Gene Related Peptide Type 1 Receptor pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, and Discovery stages are 4, and 2 respectively.

Calcitonin Gene Related Peptide Type 1 Receptor overview

Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor. The association of CALCRL with different RAMP proteins produces different receptors which with RAMP1 acts as a receptor for calcitonin-gene-related peptide, with RAMP2 acts as a receptor for adrenomedullin-1and with RAMP3 act as a receptor for adrenomedullin-2. It plays an important role in treatment of migraine.

For a complete picture of Calcitonin Gene Related Peptide Type 1 Receptor’s drug pipeline, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.